Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 8:6:131-9.
doi: 10.2147/DMSO.S43403. Print 2013.

Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity

Jin Hee Shin  1 , Kishore M Gadde
Affiliations

Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity

Jin Hee Shin et al. Diabetes Metab Syndr Obes. .

Abstract

Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an anorexigenic agent, which is approved for the short-term treatment of obesity, while topiramate is approved for nonweight loss indications - seizure disorders and migraine prophylaxis. The amount of weight loss achieved with combination therapy is of a greater magnitude than what could be achieved with either agent alone. Adverse events that occur with the combination therapy are in line with the known side effect profiles of the constituent drugs; teratogenicity, a slight increase in heart rate, psychiatric and cognitive adverse effects, and metabolic acidosis are concerns.

Keywords: Qsymia; antiobesity drugs; combination drug; obesity; phentermine; topiramate; weight loss.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization. Obesity and overweight [webpage on the Internet] Geneva: World Health Organization; 2012. [Accessed March 25, 2013]. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html.
    1. James WP. The epidemiology of obesity: the size of the problem. J Intern Med. 2008;263(4):336–352. - PubMed
    1. Haslam DW, James WP. Obesity. Lancet. 2005;366(9492):1197–1209. - PubMed
    1. Overweight, obesity, and health risk. National Task Force on the Prevention and Treatment of Obesity. Arch Intern Med. 2000;160(7):898–904. - PubMed
    1. Kramer FM, Jeffery RW, Forster JL, Snell MK. Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women. Int J Obes. 1989;13(2):123–136. - PubMed

LinkOut - more resources

-